{"id":475533,"date":"2020-03-23T12:14:01","date_gmt":"2020-03-23T12:14:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=475533"},"modified":"2020-03-23T12:14:01","modified_gmt":"2020-03-23T12:14:01","slug":"acute-lymphoblastic-leukemia-market-size-and-share-market-trends-and-forecast-to-2030","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/acute-lymphoblastic-leukemia-market-size-and-share-market-trends-and-forecast-to-2030_475533.html","title":{"rendered":"Acute Lymphoblastic Leukemia Market Size and Share, Market trends and forecast to 2030"},"content":{"rendered":"
\"Acute<\/a><\/div>\n
DelveInsight’s “Acute Lymphoblastic Leukemia (ALL) – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Acute Lymphoblastic Leukemia (ALL), historical and forecasted epidemiology as well as the Acute Lymphoblastic Leukemia (ALL) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<\/div>\n

Albany, NY –<\/strong> DelveInsight launched its new report on Acute Lymphoblastic Leukemia (ALL) – Market Insights, Epidemiology, and Market Forecast-2030<\/a>.<\/p>\n

DelveInsight’s “Acute Lymphoblastic Leukemia (ALL) – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Acute Lymphoblastic Leukemia (ALL), historical and forecasted epidemiology as well as the Acute Lymphoblastic Leukemia (ALL) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n

The key facts of the report:<\/strong>
1. The adult acute lymphoblastic leukaemia incidence is about 1 in 100,000.
2. There are estimated 5930 new cases of acute lymphoblastic leukemia in which 3280 are males and 2650 are females.<\/p>\n

Key benefits of the report:<\/strong>
1. Acute lymphoblastic leukemia market report covers a descriptive overview and comprehensive insight of the Acute lymphoblastic leukemia epidemiology and Acute lymphoblastic leukemia market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Acute lymphoblastic leukemia market report provides insights on the current and emerging therapies.
3. Acute lymphoblastic leukemia market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Acute lymphoblastic leukemia market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Acute lymphoblastic leukemia market.<\/p>\n

\"\"<\/p>\n

Request for sample pages<\/strong>: https:\/\/www.delveinsight.com\/sample-request\/acute-lymphoblastic-leukemia-all-market<\/p>\n

The key players in Acute lymphoblastic leukemia market are:<\/strong>
1. Allogene Therapeutics
2. Autolus Therapeutics
3. Kite Pharma
4. Sanofi
5. Sun Pharma Advanced Research
6. Takara Bio<\/p>\n

Drugs covered are:<\/strong>
1. AUTO3
2. KTE-X19
3. Isatuximab
4. TBI-1501
5. BinD 19
6. K0706<\/p>\n

Table of contents:<\/strong><\/p>\n

1. Report Introduction
2. Acute Lymphoblastic Leukemia Market Overview at a Glance
3. Acute Lymphoblastic Leukemia Disease Background and Overview
4. Acute Lymphoblastic Leukemia Epidemiology and Patient Population
4.1. Assumptions and Caveats
4.2. 7MM Incident cases of Acute Lymphoblastic Leukemia (2017–2028)
4.3. Age-Specific cases of Acute Lymphoblastic Leukemia (2017–2028)
4.4. Gender-Specific cases of Acute Lymphoblastic Leukemia (2017–2028)
4.5. Diagnosed and Treatable cases of Acute Lymphoblastic Leukemia (2017–2028)
4.6. Acute Lymphoblastic Leukemia: Country- Wise Epidemiology
4.7. United States
4.8. EU-5
4.9. Assumptions and Rationale
4.10. Germany
4.11. France
4.12. Italy
4.13. Spain
4.14. United Kingdom
4.15. Japan
5. Acute Lymphoblastic Leukemia Treatments & Medical Practices
6. Acute Lymphoblastic Leukemia Marketed Therapies
6.1. Kymriah: Novartis
6.2. Besponsa: Pfizer
6.3. Blinatumomab: Amgen
7. Acute Lymphoblastic Leukemia Emerging Therapies
8. Key Cross Competition
8.1. AUTO3: Autolus Therapeutics
8.2. Isatuximab: Sanofi
8.3. KTE-X19: Kite Pharma
8.4. TBI-1501:Takara Bio
9. Acute Lymphoblastic Leukemia Market Size
10. 7MM Acute Lymphoblastic Leukemia: Country-Wise Market Analysis
11. United States Market Size
12. Germany Market Size
13. France Market Size
14. United Kingdom Market Size
15. Spain Market Size
16. Italy Market Size
17. Japan Market Size
18. Acute Lymphoblastic Leukemia Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight<\/p>\n

Related reports:<\/strong><\/p>\n

Acute Lymphoblastic Leukemia (ALL) – Epidemiology Forecast to 2030<\/a><\/p>\n

Acute Lymphoblastic Leukemia (ALL) Pipeline Insight, 2020<\/a> <\/p>\n

Media Contact<\/span>
Company Name:<\/strong> DelveInsight Business Research LLP<\/a>
Contact Person:<\/strong> Kritika Rehani
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> +919650213330
Address:<\/strong>304 S. Jones Blvd #2432
City:<\/strong> Albany
State:<\/strong> New York
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.delveinsight.com\/<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

DelveInsight’s “Acute Lymphoblastic Leukemia (ALL) – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Acute Lymphoblastic Leukemia (ALL), historical and forecasted epidemiology as well as the Acute Lymphoblastic Leukemia (ALL) market trends in the United … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-475533","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/475533","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=475533"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/475533\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=475533"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=475533"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=475533"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}